PDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Inspirion Wealth Advisors LLC

Inspirion Wealth Advisors LLC lowered its stake in PDS Biotechnology Co. (NASDAQ:PDSB) by 4.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 344,394 shares of the company’s stock after selling 15,500 shares during the quarter. Inspirion Wealth Advisors LLC owned about 0.94% of PDS Biotechnology worth $1,316,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Kathleen S. Wright Associates Inc. acquired a new position in PDS Biotechnology in the 1st quarter worth $28,000. Tempus Wealth Planning LLC acquired a new position in shares of PDS Biotechnology in the second quarter worth about $55,000. Ground Swell Capital LLC purchased a new position in PDS Biotechnology in the second quarter valued at about $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in PDS Biotechnology during the 2nd quarter valued at approximately $115,000. Finally, Squarepoint Ops LLC purchased a new stake in PDS Biotechnology during the 2nd quarter worth approximately $120,000. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

PDS Biotechnology Stock Performance

Shares of NASDAQ:PDSB traded down $0.25 on Friday, hitting $3.71. The company’s stock had a trading volume of 719,878 shares, compared to its average volume of 644,373. The company has a market capitalization of $136.08 million, a price-to-earnings ratio of -2.73 and a beta of 1.88. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84. PDS Biotechnology Co. has a 12 month low of $2.53 and a 12 month high of $6.85. The stock’s 50-day moving average is $3.24 and its two-hundred day moving average is $3.35.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter in the prior year, the firm earned ($0.37) earnings per share. On average, equities research analysts forecast that PDS Biotechnology Co. will post -1.3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PDSB. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research note on Wednesday. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. Finally, B. Riley reduced their price objective on PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, June 12th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.25.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.